Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc.SNOA · Entity 8177 | Director | July 09, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sonoma Pharmaceuticals, Inc.
Report date July 09, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-07-09 | Direct | 30,001 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 10,000 · Balance 30,001 F2: The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors. F1: The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control.
F2: The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 10, 2026 00:47 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $1.26 | Not disclosed |
DisclosureSEC source: 0001683168-26-005423 · ownership.xml · derivative · entry 1 Weigerstorfer Philippe · CIK 0001751449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,001 Underlying: Common Stock · 10,000 shares Expires 2036-07-09 F2 · price: The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors. F1 · derivative.exercise_date: The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 22:25 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $3.68 | Not disclosed |
DisclosureSEC source: 0001683168-26-000045 · ownership.xml · derivative · entry 1 Weigerstorfer Philippe · CIK 0001751449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,001 Underlying: Common Stock · 10,000 shares Expires 2036-01-02 F2 · price: The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors as part of the Company's annual grant of stock options. F1 · derivative.exercise_date: The options vest one third each on 1/2/2027, 1/2/2028 and 1/2/2029, or upon change of control. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:02 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 7,500 | Not disclosed Strike: $2.68 | Not disclosed |
DisclosureSEC source: 0001683168-25-000080 · ownership.xml · derivative · entry 1 Weigerstorfer Philippe · CIK 0001751449 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,001 Underlying: Common Stock · 7,500 shares Expires 2035-01-02 F2 · price: The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors as part of the Company's annual grant of stock options. F1 · derivative.exercise_date: The options vest one third each on 1/2/2026, 1/2/2027 and 1/2/2028, or upon change of control. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 22:02 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001683168-22-008721 · ownership.xml · derivative · entry 1 Weigerstorfer Philippe · CIK 0001751449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 20,000 shares Expires 2032-12-29 F2 · price: The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors as part of the Company's annual grant of stock options. F1 · derivative.exercise_date: The options vest one third each on 12/29/2023, 12/29/2024 and 12/29/2025, or upon change of control. Read SEC document |
| January 14, 2022 Filed Jan 15, 2022 01:34 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001683168-22-000280 · ownership.xml · derivative · entry 1 Weigerstorfer Philippe · CIK 0001751449 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common stock · 30,000 shares Expires 2032-01-14 F2 · price: The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors. F1 · derivative.exercise_date: The options vest 10,000 each on 07/14/2022, 07/14/2023 and 07/14/2024, or upon change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.